The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug
...
Monitoring. This text was developed in consultation with the WHO Collaborating Centre for International Drug Monitoring and the national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring.
more
Available in Arabic, Chinese, English, French, Portuguese, Russian and Spanish
https://apps.who.int/iris/handle/10665/334254
Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report
...
on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019) presents a decade’s worth of data on drug efficacy and surveillance, as well as recommendations to monitor and protect the efficacy of malaria treatment in the decades to come.
more
The well-being of children in sub-Saharan Africa is under siege from all directions since the advent of the COVID-19 pandemic. The region is now suffering its first-ever economic recession, pushing about 50 million people into extreme poverty, a majority of whom are children.
Cette évaluation a trois principaux objectifs :
1 - Evaluer la qualité des données collectées par le système LP depuis septembre 2010 à septembre 2012.
2 - En fonction de la qualité de ces données, appuyer l’équipe terrain, basée principalement à Diapaga, dans l’analyse statistique
...
des données, particulièrement des données nutritionnelles.
3 - Enfin, analyser l’ensemble du système de gestion des données existant et proposer des améliorations du système depuis la phase de collecte, de saisie, de traitement et d’analyse des données jusqu’à la valorisation des résultats et la dissémination des rapports.
more
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir
...
st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
8 January 2021
Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. Continued genome sequencing supports the monitoring of the disease’s spread and evolution of the virus. Accelerated integration of genome sequencing int
...
o the practices of the global health community is required if we want to be better prepared for the future threats. This document provides guidance for laboratories on maximizing the impact of SARS-CoV-2 sequencing now and other emerging pathogens in the future.
more
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
Coronavirus – wir informieren in mehreren Sprachen
Die Informationen werden laufend erweitert und aktualisiert.
Le présent guide qui comprend une liste consensuelle de quarante-cinq (45) maladies,
affections et évènements prioritaires est structuré en une partie introductive comportant des définitions et généralités et de neuf (09) sections.
Les 9 sections sont :
i) identifier les cas de maladies,
...
affections prioritaires et évènements
de santé publique
ii) notifier les maladies, affections prioritaires et évènements de santé publique
iii) analyser les données
iv) investiguer les flambées épidémiques notifiées et autres évènements de santé publique
v) se préparer à riposter aux épidémies et autres évènements de santé publique
vi) répondre aux épidémies et autres évènements de santé publique
vii) communiquer l‟information
viii) suivre, évaluer et améliorer la surveillance et la riposte
ix) récapitulatif des directives relatives aux maladies, affections prioritaires
spécifiques et évènements de santé publique
more
WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI
...
D-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir
...
respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method
...
ology issues there are still insufficient data to make a recommendation, in which case different options for approaching VE evaluations are presented.
more
These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older